Art of Capital
Contributor since: 2016
Latest Articles
Aratana Therapeutics: Slow Out Of The Gates
Peanut Wars: Things Are Heating Up Between Aimmune Therapeutics And DBV Technologies
Titan Pharmaceuticals: Outlook For Probuphine
Fear And Greed Explorations: It's A Risk-Off/U.S. Dollar Story That Is Driving Gold
Cara Therapeutics: A Look At The Next Catalyst - Osteoarthritis
Fear And Greed Explorations: Bearish And Bottomless
Fear And Greed Explorations: What Caused Gold's Move Lower?
Fear And Greed Explorations: 7 Reason Why The SLV Will Not Hit 17
Fear And Greed Explorations: Gold
Fear And Greed Explorations: Silver Is In A No Man's Land
Fear And Greed Explorations: Continued Consolidation
Opportunity In Focus: Ocular Therapeutix Is A Solid Speculation
Developmental Stage Bios To Watch: Pieris Pharmaceuticals
Aratana Therapeutics: Update On The Rollout Of Galliprant And Nocita
Fear And Greed Explorations: Is A Pullback In Gold Looming?
Fear And Greed Explorations: Breaking Down The Silver Trade
Fear And Greed Explorations: A Massive Cup And Handle Is Now Fully Formed
GW Pharmaceuticals: Up 188%, But I'm Not Selling
Fear And Greed Explorations: SLV Breaks Out From A 9-Month Downtrend
Fear And Greed Explorations: Gold Bulls Hope That The 3rd Time Is A Charm
Fear And Greed Explorations: A Bull Cycle In Silver?
Fear And Greed Explorations: GLD Has Reached A Critical Inflection Point
Fear And Greed Explorations: Unwind Of The Dollar/Gold Trade
Protalix BioTherapeutics: Exploring Ulcerative Colitis
Under The Radar: Aratana Therapeutics
Fear & Greed Explorations: GLD
Fear & Greed Explorations: The GLD
Set To Explode: Ritter Pharmaceuticals
Market Analysis: Titan's Probuphine Faces Challenges Ahead
Opportunity In Focus: Buy GLD
A Look At U.S. Markets: A Historical Analysis, Different Forms Of Valuing The Market And 3 Large Concerns
Cara Therapeutics: A Look At The Next Catalyst - Uremic Pruritus